+ Filter

Anti-BCR-ABL Recombinant Antibody Products

Anti-BCR-ABL Products

A*02:01/Human BCR-ABL (GVRGRVEEI) MHC Monomer (MHC-YF298)
- Class: Class I
- Antigen: BCR-ABL
- Antigen Species: Human
- Peptide: GVRGRVEEI
- Conjugate: Biotin
Compare

Human Anti-BCR-ABL Recombinant Antibody (clone 7c6) (FAMAB-1599CQ)
- Species Reactivity: Human
- Type: Human IgG1
- Application: IP, WB, IF, IHC
Compare

Anti-BCR-ABL (clone W24V154) Recombinant Antibody Coupled Liposome (VS-1024-FY155) (VS-1024-FY155)
- Antibody Host: Human
- Antibody Reactivity: Human
Compare

More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.

Creative Biolabs offers an extensive range of BCR-ABL recombinant antibody products with unparalleled technical support. Our team of experts is dedicated to assisting researchers with experimental design, assay optimization, troubleshooting, and data analysis. With our support, you can confidently use our antibody for your research and achieve reliable, accurate results.

BCR-ABL: A Responsive and Functional Tumor Target

The BCR-ABL fusion protein, a nonreceptor tyrosine kinase resulting from the Philadelphia chromosome abnormality, demonstrates enhanced tyrosine kinase activity relative to the normal c-Abl protein. This aberrant activity disrupts normal cell cycle regulation, promoting cell survival and proliferation by activating pathways such as RAS and STAT. Consequently, targeting BCR-ABL represents a promising therapeutic strategy for cancer treatment.

Alternative Names

BCR-ABL; Breakpoint cluster region protein-tyrosine protein kinase ABL1 fusion protein

Background

This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and stress response. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons.

Anti-BCR-ABL rAb Products

Our anti-BCR-ABL recombinant antibodies consist of monoclonal antibodies designed to selectively bind to the BCR-ABL. These antibodies are designed for enhanced precision and efficacy, guaranteeing consistent and trustworthy outcomes. Our comprehensive collection of anti-BCR-ABL recombinant antibodies provides researchers with a versatile array of options to suit their specific experimental needs. Meanwhile, our antibodies are available in a variety of formulations and conjugates, designed to accommodate a wide range of research methodologies and applications.

Table 1. Featured anti-BCR-ABL recombinant antibody products at Creative Biolabs.

Cat. No.	Product Name	Target Species	Host Species	Applications
FAMAB-1599CQ	Human Anti-BCR-ABL Recombinant Antibody (clone 7c6)	Human	Human IgG1	IP, WB, IF, IHC

Creative Quality Control

Creative Biolabs is committed to delivering the highest quality BCR-ABL recombinant antibodies. Our stringent quality assurance systems guarantee that each product adheres to high standards of purity, efficacy, precision, and reliability. This dedication to quality allows researchers and clinicians to rely on our antibodies for their immunotherapy and cancer research endeavors.

Customer Reviews

Excellent

An***a
Human Anti-BCR-ABL Recombinant Antibody (clone 7c6) (CAT#: FAMAB-1599CQ)

I recently used the Human Anti-BCR-ABL Recombinant Antibody (clone 7c6) for an IP assay and was highly impressed by its performance. The antibody exhibited excellent specificity for the BCR-ABL fusion protein, effectively isolating it from complex samples, even at low concentrations. Its recombinant nature ensured consistent quality and reproducibility, making it suitable for various downstream applications like Western blotting, immunohistochemistry, and ELISA. Overall, I am extremely satisfied with the Human Anti-BCR-ABL Recombinant Antibody (clone 7c6) and highly recommend it to other researchers working on BCR-ABL-related studies.

11/Oct/2023

Excellent

Cr***l
Human Anti-BCR-ABL Recombinant Antibody (clone 7c6) (CAT#: FAMAB-1599CQ)

I tried out the Human Anti-BCR-ABL Recombinant Antibody (clone 7c6) from Creative Biolabs for an IF assay and was pretty stoked with the results. It did a great job staining BCR-ABL-positive cells, and the recombinant nature made it super reliable. Definitely a solid choice for anyone working on BCR-ABL research.

16/Feb/2024

rAb Production

Creative Biolabs' anti-BCR-ABL recombinant antibody production platform utilizes cutting-edge genetic engineering technology to generate antibodies with exceptional specificity and affinity. Our scalable production capabilities enable us to deliver large quantities of antibodies at competitive prices, meeting the growing demand for this essential research tool.

Featured Anti-BCR-ABL Recombinant Antibody Production Platforms Fig.1 Milligram-scale. (Creative Biolabs Original)
Fig.1 Milligram-scale anti-BCR-ABL recombinant antibody production.

Fig.2 Gram-scale. (Creative Biolabs Original) Fig.2 Gram-scale anti-BCR-ABL recombinant antibody production.

rAb Modalities

Creative Biolabs is dedicated to delivering cutting-edge anti-BCR-ABL recombinant antibodies in a variety of formats to support your research goals.

Fig.3 BCR-ABL antibody production and modalities. (Creative Biolabs Original) Fig.3 Full-length anti-BCR-ABL recombinant antibody production and modalities.

BCR-ABL-Targeted Drug Information

Table 2. Public drug targeting BCR-ABL.

Highest Phase	Mechanism of Action	Product Category	Condition	Organization
Preclinical	Anti-Bcr-Abl (Bcr-Abl1) Kinase Transferrin Receptor Protein 1 (TFRC; TfR; CD71) Ligands	Cancer Immunotherapy Nanoparticles Polypeptides, from 41 AA Rabbit Monoclonal Antibodies	Chronic myeloid leukemia	Chongqing Medical University International Institute of In Vitro Diagnostics (Originator)
Preclinical	Bcr-Abl (Bcr-Abl1) Kinase Gene Editing	CRISPR/Cas9 System Nucleases Single Guide RNA (sgRNA) Single-stranded oligoribonucleotide (RNA)	Cancer	Centro Nac Investigaciones Oncologicas (Originator)
Biological Testing	Bcr-Abl (Bcr-Abl1) Kinase Degradation Inducers Drugs Targeting E3 Ubiquitin-Protein Ligase RNF114 Signal Transduction Modulators	Pegylated Drugs PROTACs (Proteolysis Targeting Chimeras)	Cancer	Novartis (Originator) University of California (Originator)
Biological Testing	Angiogenesis Inhibitors Bcr-Abl (Bcr-Abl1) Kinase Inhibitors Bruton's Tyrosine Kinase (BTK) Inhibitors Discoidin Domain-Containing Receptor 1 (DDR1) Inhibitors Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors Ephrin (EPH) Receptor Inhibitors KIT (c-KIT) (Leu576Pro Mutant) Inhibitors Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R; CD115; c-Fms) Inhibitors Mast/Stem Cell Growth Factor Receptor Kit (KIT; c-KIT; CD117) Inhibitors PDGFRalpha Inhibitors Platelet-Derived Growth Factor Receptor beta (PDGFRB) Inhibitors Proto-Oncogene Tyrosine-Protein Kinase Src (SRC; SRC1) Inhibitors Signal Transduction Modulators Tyrosine Protein Kinase Blk Inhibitors Tyrosine-Protein Kinase ABL1 (ABL) Inhibitors Tyrosine-Protein Kinase CSK Inhibitors Tyrosine-Protein Kinase Fgr Inhibitors Tyrosine-Protein Kinase FRK Inhibitors Tyrosine-Protein Kinase Fyn Inhibitors Tyrosine-Protein Kinase HCK Inhibitors Tyrosine-Protein Kinase Lck Inhibitors Tyrosine-Protein Kinase Lyn Inhibitors Tyrosine-Protein Kinase Yes (YES1) Inhibitors	Oligopeptides, less than 10 AA Peptide-Drug Conjugates RGD peptides	Cancer	Inner Mongolia Medical University (Originator)
Biological Testing	Apoptosis Inducers Bcr-Abl (Bcr-Abl1) Kinase Degradation Inducers Drugs Targeting Inhibitor of Apoptosis Proteins (IAP) Signal Transduction Modulators	Oligopeptides, less than 10 AA Pegylated Drugs PROTACs (Proteolysis Targeting Chimeras) SNIPERs (Specific and Nongenetic IAP-Dependent Protein Eraser)	Leukemia	Takeda (Originator)
Biological Testing	Bcr-Abl (Bcr-Abl1) Kinase (Thr315Ile Mutant) Inhibitors Bcr-Abl (Bcr-Abl1) Kinase Inhibitors Signal Transduction Modulators	Pegylated Drugs	Chronic myeloid leukemia	BlinkBio (Originator)
Biological Testing	Bcr-Abl (Bcr-Abl1) Kinase (Thr315Ile Mutant) Inhibitors Bcr-Abl (Bcr-Abl1) Kinase Inhibitors Signal Transduction Modulators	Pegylated Drugs	Chronic myeloid leukemia	BlinkBio (Originator)
Biological Testing	Bcr-Abl (Bcr-Abl1) Expression Inhibitors	Oligonucleotides Small Interfering RNA (siRNAs)	Chronic myeloid leukemia	Universitaet Duisburg-Essen (Originator)

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

To explore the possibilities of anti-BCR-ABL antibody products for your research or clinical applications, please do not hesitate to contact us. We are focused on delivering extensive assistance and informational resources to meet your needs. Let's collaborate to advance innovative solutions in cancer treatment.